Serum Iron Level Is Associated with Time to Antibiotics in Cystic Fibrosis

Overview

Journal Clin Transl Sci

Specialties Biomedical Engineering
General Medicine

Date 2015 Dec 9

PMID 26643575

Citations 3

Authors

Alex H Gifford

Dana B Dorman

Lisa A Moulton

Jennifer E Helm

Mary M Griffin

Todd A MacKenzie

Affiliations

Soon will be listed here.

Abstract

Background: Serum levels of hepcidin-25, a peptide hormone that reduces blood iron content, are elevated when patients with cystic fibrosis (CF) develop pulmonary exacerbation (PEx). Because hepcidin-25 is unavailable as a clinical laboratory test, we questioned whether a one-time serum iron level was associated with the subsequent number of days until PEx, as defined by the need to receive systemic antibiotics (ABX) for health deterioration.

Methods: Clinical, biochemical, and microbiological parameters were simultaneously checked in 54 adults with CF. Charts were reviewed to determine when they first experienced a PEx after these parameters were assessed. Time to ABX was compared in subgroups with and without specific attributes. Multivariate linear regression was used to identify parameters that significantly explained variation in time to ABX.

Results: In univariate analyses, time to ABX was significantly shorter in subjects with Aspergillus-positive sputum cultures and CF-related diabetes. Multivariate linear regression models demonstrated that shorter time to ABX was associated with younger age, lower serum iron level, and Aspergillus sputum culture positivity.

Conclusions: Serum iron, age, and Aspergillus sputum culture positivity are factors associated with shorter time to subsequent PEx in CF adults.

Citing Articles

Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis.

Jia S, Wang Y, Ross M, Zuckerman J, Murray S, Han M J Cyst Fibros. 2024; 23(5):878-884.

PMID: 38490920 PMC: 11399321. DOI: 10.1016/j.jcf.2024.03.002.

Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa survival.

Hazlett H, Hampton T, Aridgides D, Armstrong D, Dessaint J, Mellinger D Sci Rep. 2020; 10(1):10935.

PMID: 32616918 PMC: 7331733. DOI: 10.1038/s41598-020-67729-5.

Microbial Metabolite Signaling Is Required for Systemic Iron Homeostasis.

Das N, Schwartz A, Barthel G, Inohara N, Liu Q, Sankar A Cell Metab. 2019; 31(1):115-130.e6.

PMID: 31708445 PMC: 6949377. DOI: 10.1016/j.cmet.2019.10.005.

References

Bakare N, Rickerts V, Bargon J, Just-Nubling G . Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses. 2003; 46(1-2):19-23. DOI: 10.1046/j.1439-0507.2003.00830.x. View

MacKenzie T, Gifford A, Sabadosa K, Quinton H, Knapp E, Goss C . Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med. 2014; 161(4):233-41. PMC: 4687404. DOI: 10.7326/M13-0636. View

Kucher N, Goldhaber S . Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation. 2003; 108(18):2191-4. DOI: 10.1161/01.CIR.0000100687.99687.CE. View

Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen B . IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113(9):1271-6. PMC: 398432. DOI: 10.1172/JCI20945. View

Fuchs H, Borowitz D, Christiansen D, Morris E, Nash M, Ramsey B . Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994; 331(10):637-42. DOI: 10.1056/NEJM199409083311003. View

Dobbin C, Bartlett D, Melehan K, Grunstein R, Bye P . The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. Am J Respir Crit Care Med. 2005; 172(1):99-104. DOI: 10.1164/rccm.200409-1244OC. View

Kraynack N, McBride J . Improving care at cystic fibrosis centers through quality improvement. Semin Respir Crit Care Med. 2009; 30(5):547-58. DOI: 10.1055/s-0029-1238913. View

Amin R, Dupuis A, Aaron S, Ratjen F . The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest. 2009; 137(1):171-6. DOI: 10.1378/chest.09-1103. View

Gifford A . What is hepcidin telling us about the natural history of cystic fibrosis?. J Cyst Fibros. 2014; 14(1):155-7. PMC: 4687399. DOI: 10.1016/j.jcf.2014.03.012. View

10.

Reid P, McAllister D, Boyd A, Innes J, Porteous D, Greening A . Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis. Am J Respir Crit Care Med. 2015; 191(2):233-6. PMC: 4347434. DOI: 10.1164/rccm.201407-1365LE. View

11.

Milla C, Wielinski C, Regelmann W . Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients. Pediatr Pulmonol. 1996; 21(1):6-10. DOI: 10.1002/(SICI)1099-0496(199601)21:1<6::AID-PPUL1>3.0.CO;2-R. View

12.

Britto M, Kotagal U, Hornung R, Atherton H, Tsevat J, Wilmott R . Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002; 121(1):64-72. DOI: 10.1378/chest.121.1.64. View

13.

Sabatine M, Morrow D, de Lemos J, Gibson C, Murphy S, Rifai N . Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002; 105(15):1760-3. DOI: 10.1161/01.cir.0000015464.18023.0a. View

14.

Que C, Cullinan P, Geddes D . Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax. 2005; 61(2):155-7. PMC: 2104571. DOI: 10.1136/thx.2005.043372. View

15.

Schluchter M, Konstan M, Drumm M, Yankaskas J, Knowles M . Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med. 2006; 174(7):780-6. PMC: 2648062. DOI: 10.1164/rccm.200512-1919OC. View

16.

Block J, Vandemheen K, Tullis E, Fergusson D, Doucette S, Haase D . Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax. 2006; 61(11):969-74. PMC: 2121166. DOI: 10.1136/thx.2006.061366. View

17.

Merlo C, Boyle M, Diener-West M, Marshall B, Goss C, Lechtzin N . Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest. 2007; 132(2):562-8. DOI: 10.1378/chest.06-2888. View

18.

Stone A, Saiman L . Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis. Curr Opin Pulm Med. 2007; 13(6):515-21. DOI: 10.1097/MCP.0b013e3282efbbac. View

19.

Mena N, Esparza A, Tapia V, Valdes P, Nunez M . Hepcidin inhibits apical iron uptake in intestinal cells. Am J Physiol Gastrointest Liver Physiol. 2007; 294(1):G192-8. DOI: 10.1152/ajpgi.00122.2007. View

20.

Theurl I, Theurl M, Seifert M, Mair S, Nairz M, Rumpold H . Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2007; 111(4):2392-9. DOI: 10.1182/blood-2007-05-090019. View